Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Coupé
Veerle M H
VM
Meijer
Chris J L M
CJ
Berkhof
Johannes
J
D052685:Alphapapillomavirus / Q000276:immunology*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D006801:Humans; D009426:Netherlands; D030361:Papillomavirus Infections / Q000191:economics / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000191:economics*; D019057:Quality-Adjusted Life Years; D014412:Tumor Virus Infections / Q000191:economics / Q000517:prevention & control* / Q000821:virology
D053918:Papillomavirus Vaccines